

30 April 2013

TENDER RESULTS

The Chief Executive under Delegated Authority has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012 and the 2010/11 Invitation to Tender, dated 02 November 2010.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12th of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

| Chemical Name | Presentation; Pack size and type | Pack price | Hospital Supply Brand (Supplier) | DV Limit | Listing date | Hospital Supply Status date |
|---------------|--------------------------------------|------------|-------------------------------------|-------------|----------------|-----------------------------|
| Paracetamol | Inj 10 mg per ml, 50 ml; 10 vials | \$22.50 | Paracetamol-AFT (AFT) | 1% | 1 October 2013 | 1 December 2013 |

2012/13 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2016

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

| Chemical Name | Presentation; Pack size and type | Current subsidy and (price) | New subsidy and price | Sole supply brand (Supplier) | Date of listing/subsidy change for tender winning brand | Date of reference pricing of other listed brands | Sole Subsidised Supply date (and delisting of other listed brands) | Brand (Supplier) affected by reference pricing and delisting |
|-----------------------------|--|-----------------------------------|--------------------------|---------------------------------|--|--|---|---|
| Alprazolam | Tab 250 mcg; 50 tablet blister pack | \$3.15 | \$2.50 | Xanax (Pfizer) | 1 November 2013 | 1 January 2014 | 1 April 2014 | Arrow-Alprazolam (Arrow) |
| Alprazolam | Tab 500 mcg; 50 tablet blister pack | \$4.10 | \$3.25 | Xanax (Pfizer) | 1 November 2013 | 1 January 2014 | 1 April 2014 | Arrow-Alprazolam (Arrow) |
| Alprazolam | Tab 1 mg; 50 tablet blister pack | \$7.25 | \$5.00 | Xanax (Pfizer) | 1 November 2013 | 1 January 2014 | 1 April 2014 | Arrow-Alprazolam (Arrow) |
| Amoxicillin | Cap 250 mg; 500 capsule bottle | \$16.18 | \$16.18 | Apo-Amoxi (Apotex) | 1 November 2013 | 1 January 2014 | 1 April 2014 | Alphamox (Mylan) |
| Amoxicillin | Cap 500 mg; 500 capsule bottle | \$26.50 | \$20.94 | Apo-Amoxi (Apotex) | 1 November 2013 | 1 January 2014 | 1 April 2014 | Alphamox (Mylan) |
| Tamsulosin hydrochloride | Cap 400 mcg; 100 capsule blister pack | \$5.98 per 30 caps | \$13.51 | Tamsulosin-REX (Rex Medical) | 1 October 2013 | 1 December 2013 | 1 March 2014 | Tamsulosin-REX (Rex Medical) 30 cap pack size |

3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

| Chemical name | Presentation; Pack size and type | Current subsidy and (price) | New subsidy and price | Sole supply brand (Supplier) | Date of subsidy change | Sole Subsidised Supply date |
|---------------------|---|-----------------------------------|-----------------------------|---------------------------------|------------------------|-----------------------------|
| Ascorbic acid | Tab 100 mg; 500 tablet bottle | \$13.80 | \$7.00 | Vitala-C (Goldshield) | 1 September 2013 | 1 December 2013 |
| Ipratropium bromide | Nebuliser soln, 250 mcg per ml, 1 ml; 20 ampoules | \$3.79 | \$3.26* | Univent (Rex Medical) | 1 July 2013 | 1 October 2013 |

| Chemical name | Presentation; Pack size and type | Current subsidy and (price) | New subsidy and price | Sole supply brand (Supplier) | Date of subsidy change | Sole Subsidised Supply date |
|-----------------------------|--|-----------------------------------|-----------------------------|---------------------------------|------------------------|-----------------------------|
| Medroxyprogesterone acetate | Tab 2.5 mg; 30 tablet blister pack | \$3.09 | \$3.09 | Provera (Pfizer) | 1 July 2013 | 1 October 2013 |
| Medroxyprogesterone acetate | Tab 5 mg; 100 tablet blister pack | \$13.06 | \$13.06 | Provera (Pfizer) | 1 July 2013 | 1 October 2013 |
| Medroxyprogesterone acetate | Tab 10 mg; 30 tablet blister pack | \$6.85 | \$6.85 | Provera (Pfizer) | 1 July 2013 | 1 October 2013 |
| Medroxyprogesterone acetate | Tab 100 mg; 100 tablet blister pack | \$96.50 | \$96.50 | Provera (Pfizer) | 1 July 2013 | 1 October 2013 |
| Medroxyprogesterone acetate | Inj 150 mg per ml, 1 ml syringe; 1 syringe | \$7.15 | \$7.00 | Depo-Provera (Pfizer) | 1 July 2013 | 1 October 2013 |
| Vitamin B complex | Tab, strong (BPC); 500 tablet bottle | \$4.70 | \$4.30 | B-PlexADE (Goldshield) | 1 September 2013 | 1 December 2013 |
| Vitamins | Tab (BPC cap strength); 1,000 tablet bottle | \$8.00 | \$7.60 | MultiADE (Goldshield) | 1 September 2013 | 1 December 2013 |

***Note** that the new pack price for the Section H listing was incorrectly notified as \$3.60 in the March 2013 notification. The correct price is \$3.26.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

| Chemical Name | Presentation; Pack size and type | Current pack price | New pack price | Hospital Supply Brand (Supplier) | DV Limit | Date of listing/price change for tender winning brand | Hospital Supply Status date (and delisting of other listed brands) | Brand (Supplier) to be delisted |
|--------------------------|--|-----------------------|----------------|----------------------------------|----------|---|--|--|
| Amoxicillin | Cap 250 mg; 500 capsule bottle | \$16.18 | \$16.18 | Apo-Amoxi (Apotex) | 1% | 1 November 2013 | 1 January 2014 | Alphamox (Mylan) |
| Amoxicillin | Cap 500 mg; 500 capsule bottle | \$26.50 | \$20.94 | Apo-Amoxi (Apotex) | 1% | 1 November 2013 | 1 January 2014 | Alphamox (Mylan) |
| Tamsulosin hydrochloride | Cap 400 mcg; 100 capsule blister pack | \$5.98 per 30 caps | \$13.51 | Tamsulosin-REX (Rex Medical) | 1% | 1 October 2013 | 1 December 2013 | Tamsulosin-REX (Rex Medical) 30 cap pack size |

5. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

| Chemical Name | Presentation; Pack size and type | Current pack price | New pack price | Hospital Supply Brand (Supplier) | DV Limit | Date of price change | Hospital Supply Status date |
|-----------------------------|---|--------------------|----------------|----------------------------------|----------|----------------------|-----------------------------|
| Ascorbic acid | Tab 100 mg; 500 tablet bottle | \$13.80 | \$7.00 | Vitala-C (Goldshield) | 1% | 1 September 2013 | 1 November 2013 |
| Ipratropium bromide | Nebuliser soln, 250 mcg per ml, 1 ml; 20 ampoules | \$3.79 | \$3.26* | Univent (Rex Medical) | 1% | 1 July 2013 | 1 September 2013 |
| Medroxyprogesterone acetate | Tab 2.5 mg; 30 tablet blister pack | \$3.09 | \$3.09 | Provera (Pfizer) | 1% | 1 July 2013 | 1 September 2013 |
| Medroxyprogesterone acetate | Tab 5 mg; 100 tablet blister pack | \$13.06 | \$13.06 | Provera (Pfizer) | 1% | 1 July 2013 | 1 September 2013 |
| Medroxyprogesterone acetate | Tab 10 mg; 30 tablet blister pack | \$6.85 | \$6.85 | Provera (Pfizer) | 1% | 1 July 2013 | 1 September 2013 |

*Note that the new pack price for the Section H listing was incorrectly notified as \$3.60 in the March 2013 notification. The correct price is \$3.26.

| Chemical Name | Presentation; Pack size and type | Current pack price | New pack price | Hospital Supply Brand (Supplier) | DV Limit | Date of price change | Hospital Supply Status date |
|--------------------------------|---|--------------------------|-------------------|-------------------------------------|-------------|----------------------|-----------------------------|
| Medroxyprogesterone acetate | Tab 100 mg; 100 tablet blister pack | \$96.50 | \$96.50 | Provera (Pfizer) | 1% | 1 July 2013 | 1 September 2013 |
| Medroxyprogesterone acetate | Inj 150 mg per ml, 1 ml syringe; 1 syringe | \$7.15 | \$7.00 | Depo-Provera (Pfizer) | 1% | 1 July 2013 | 1 September 2013 |

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

The Chief Executive under Delegated Authority resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2012/13 Invitation to Tender, dated 31 October 2012:

| Chemical Name | Line Item | Chemical Name | Line Item |
|-----------------------------|------------|-------------------|-----------------------|
| Medroxyprogesterone acetate | Tab 200 mg | Iodine supplement | Tab 150 mcg elemental |

For products included in the 2011/12 Invitation to Tender or the 2012/13 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.